Therapy Name | Paclitaxel + Reparixin |
Therapy Description |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Paclitaxel | Taxol | 7-Epipaclitaxel | Antimicrotubule Agent 11 BCL2 Family Inhibitor 6 | Taxol (paclitaxel) binds to tubulin to inhibit microtubule disassembly, which results in decreased cell division, and also binds to the anti-apoptotic factor Bcl-2, promoting apoptosis (NCI Drug Dictionary). |
Reparixin | Reparixin binds to and inhibits signaling of CXC chemokine receptor type 1 (CXCR1), which may lead to depletion of cancer stem cells (PMID: 20051626). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References | Unknown unknown | Her2-receptor negative breast cancer | not applicable | Paclitaxel + Reparixin | Phase Ib/II | Actionable | In a Phase Ib trial, the combination therapy of Taxol (paclitaxel) and Reparixin in patients with metastatic ERBB2 (HER2)-receptor negative breast cancer resulted in a 30% (8/27) response rate and a durable response greater than 12 months in two patients (PMID: 28539464; NCT02001974). | 28539464 |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status |
---|